
NVIDIA's BioNeMo Bets Signal a Tectonic Shift in Pharma R&D Capital Allocation
NVIDIA is positioning BioNeMo as the dominant AI infrastructure layer for pharmaceutical drug discovery, anchored by high-profile partnerships with Eli Lilly and Thermo Fisher. The consolidation of lab automation, biological foundation models, and cloud-scale compute onto a single platform is reshaping how biotech R&D pipelines are financed and built. For investors, the dynamic mirrors NVIDIA's enterprise AI playbook — and suggests a structural reallocation of capital toward platform-dependent b







